Archives: BioMedWire

July 24, 2020 14:09:12

Internet use in the medical industry has tremendously grown over the past years. The continual propagation of mobile medical devices and the amount of data in hospitals are trends medical device manufacturers should keep in mind. Also, tracking cyber-security trends should be the main aim of device manufacturers due to an increased number of cyber-attacks on medical devices. Since lives are at stake, the FDA has stepped in to guide manufacturers to ensure the safety of medical devices in the global internet world. It has called for the protection of these devices as hackers may hack them for malicious purposes.

How Hackers can Hack and Use Medical Devices

Most of the systems in the hospitals have high levels of security. However, medical devices may be an area of vulnerability and these medical devices are the point where the hackers may find entry into hospital systems. The main aim of hacking the systems is not to harm the patients but to have access to research data and patients’ records. In turn, the information is used by hackers…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Provides Standout Solution for Digital Diabetes Management

July 24, 2020 12:48:39

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, was recently featured in a Data Bridge Market Research report. The piece highlighted DarioHealth’s advancements in digital diabetes management, a rapidly growing market expected to become the “next best thing” in the wake of the current coronavirus pandemic that has made it more difficult for patients to receive treatment. A recent article discussing the company’s standout solution reads, “With 4.9 stars on the Apple App Store and 11,000 reviews, Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is a popular product with over 50,000 consumers around the globe. With a powerful commitment and contribution to chronic condition management through innovative digital-therapeutic solutions, including a novel method for chronic-disease data management, the company is rapidly moving toward addressing new chronic conditions and into new geographic markets.”

To view the full article, visit http://ibn.fm/8xeWV

About DarioHealth Corp.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AIkido Pharma Inc. (NASDAQ: AIKI) Provides Update on Computational Approaches to Identify Virus Treatments

July 24, 2020 11:59:05

AIkido Pharma (NASDAQ: AIKI) recently provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic. According to the update, AIkido previously announced an executed a master license agreement with the University of Maryland, Baltimore (“UMB”), covering certain antiviral compounds discovered by UMB. Recently, UMB researchers have identified a human protein complex (called the “SKI” complex) that is important for replication of several viruses including Influenza, COVID-19, SARS1, MERS, SARS2, Ebola and Marburg. Utilizing information gleaned from initial research and the power of a computer modeling approach called SILCS, combined with machine learning tools, the researchers are currently identifying and testing compounds with chemical structures similar to the active compounds to find ones that are efficient at blocking virus replication. “This is encouraging progress, demonstrating the importance of machine learning to accelerate pharmaceutical research,” commented Anthony Hayes, CEO of AIkido. “Legacy processes, involving manually testing potentially thousands of compounds, are slower and potentially more expensive. Utilizing a combination of a physics-based approach and machine learning, our partners are able to significantly narrow the range of potential compounds to test, accelerating efforts and significantly reducing costs. The ultimate goal is to create a new compound that blocks replication of a wide variety of viruses in humans that will be an effective drug for the treatment of known viral infections as well as those that may arise in the future.”

To view the full press release, visit http://ibn.fm/Nrafw

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and AIkido is currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Its diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (“AML”) and acute lymphoblastic leukemia (“ALL”). In addition, AIkido is constantly seeking to grow its pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus. For more information about AIkido, visit www.AIkidoPharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Digital Therapeutics Platform Builder DarioHealth Corp. (NASDAQ: DRIO) Makes International Leap with Williams Medical Partnership

July 24, 2020 10:41:44

DarioHealth Corp. is providing innovative solutions to medical patient care through its technology enabled remote patient monitoring platform (“RPM”), which it believes will save medical providers time while allowing them to better control care
The company announced its first two remote patient monitoring agreements in North America last month
On July 20, DarioHealth announced a strategic partnership that will allow the company to expand the reach of its remote patient care management internationally, targeting markets in the United Kingdom and Ireland
The ongoing COVID-19 pandemic has made tech enabled remote patient care increasingly popular as a general solution to maintaining health measures while minimizing the risk of virus transmission
The remote patient monitoring services market is expected to grow at a CAGR of 17.8 percent between 2019 and 2026

Digital therapeutics innovator DarioHealth (NASDAQ: DRIO) is building bridges that will help it cross over the Atlantic Ocean and begin serving Europeans with the company’s health monitoring solution.

The company announced July 20 that it has entered into a strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to healthcare professionals across the…

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

COVID-19 Outbreak Causes Inventor to Regret Not Patenting the Handwashing Bucket

July 24, 2020 08:59:08

Since the outbreak of COVID-19, a lot of industries have come to a standstill and most institutions and research centers have scrambled to look for ways to control and curb this deadly pandemic. Interestingly, the pandemic has also brought a lot of regrets to some inventors. The regret comes as a result of not owning the rights of their inventions, especially now when the whole world is struggling to fight the virus.

The Handwashing Bucket Inventor is Full of Regret

Veronica Beckeo is one of the inventors who have lamented as their ideas were not patented before the outbreak of the pandemic. She came up with the idea of the handwashing bucket over three decades ago in Ghana, and this handwashing bucket has been useful to many people in rural areas where running water…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Mistakes Medical Device Makers Need to Avoid

July 23, 2020

July 23, 2020 14:29:04

When coming up with medical devices, you need to be very cautious and innovative. Getting FDA regulatory approval for these devices is not always a walk in the park, and the approval process to market may be very delicate. To make that journey smoother, here are some of the mistakes that medical device innovators need to avoid.

Never Anticipate Your First Roll Out to Be Magnificent

Medical device start-ups try to give their products every possible feature they ever dreamt of. However, this overzealousness may lead device makers to include some features that are not critical to the way the world works. When a lot of sophisticated features are added…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

VA Plans to Digitize Its Electronic Health Records

July 23, 2020

July 23, 2020 09:05:06

With the emergence of new technology, the Veterans Affairs Department in on the verge of overhauling its electronic health record system. As innovations are coming into existence, there is also a need to digitize the health records. Besides, the department wants to examine if the robotic automation of health records can work. The first deployment of the electronic health record was planned to take place at Mann-Grandstaff Medical Center in Spokane, Washington, in March. Congress later pushed the launch to July, but it did not materialize. However, the launch did not take place in July as the Veteran Affairs Department was also engaged in the fighting the COVID-19 pandemic.

Digitalization of Electronic Health Records

As the system is almost reaching its full capacity, VA staff and health care providers will have to ensure all the records are digitalized, and they will also be linked with the correct patients and clinicians. However, this process of deploying and integrating electronic health systems is always complicated if the data is not machine-readable. To manage this, The VA is adopting robotic process…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Wearable Tech Could Play a Strong Role in Health If These Issues Are Addressed

July 22, 2020 13:48:53

Wearable technology is one of the latest and upcoming trends in medicine. Patients’ outcomes, population and other emerging trends are also going to improve due to the growing prominence of the fitness tracking device. This fitness tracking device is also gaining pace in the U.S. as most adults are using it in tracking their fitness habits. However, if the issues below are addressed, then wearable technology will play a smart role in improving the health sector.

The wearable Market Should Start Growing at a Steady Pace

Recent surveys show that 25.1% of adults are the only ones using fitness tracking devices. This percentage is meagre, and for the wearable to gain pace, then it needs to improve. However, it has been noted that from 2012 onwards, the number of those using the application doubled from the previous years. Besides, as more people adopt such technology and keep on relying on it, then the vendors will have to discuss how to keep on improving. Patients also need to be encouraged on the usage of these devices to gain more…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) on ‘Cash Runway’ to Fund Key Milestones

July 22, 2020 12:22:50

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is on a well-funded path to move forward with its goals. A recent article discussing this quotes POAI CEO Dr. Carl Schwartz, who states, “[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity. This action demonstrates my confidence in the commercial viability of our work, and when combined with the additional capital we raised through an equity offering, provides us with the cash runway to fund key clinical, regulatory and operational milestones for the next several quarters. In addition, we have significantly reduced the corporate structure of our Skyline Medical business to enable it to operate independently as we consider strategic alternatives for this business.”

To view the full article, visit http://ibn.fm/kGMZk

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology Inc. (NASDAQ: POAI) Finalizes Acquisition Deal Expected to Revolutionize Role of AI-Driven Predictive Models

July 22, 2020 10:38:57

POAI completes acquisition designed to accelerate commercialization of proprietary AI-driven drug discovery, development
Strategic move allows for one-of-a-kind, end-to-end ‘discovery machine’ that can rapidly generate potential therapeutic candidates
Company to offer new capability to pharmaceutical company customers in revenue-generating projects later this year

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, has completed its acquisition of Quantitative Medicine (“QM”) (http://ibn.fm/vqmwL). POAI signed a letter of intent to acquire QM, a biomedical analytics and computational biology company, in January (http://ibn.fm/4iRTV). The strategic move should accelerate the commercialization of Predictive Oncology’s proprietary AI-driven drug discovery and development.

“This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” said POAI CEO Dr. Carl Schwartz. “Integrating QM’s proven machine-learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Promises and Challenges of Machine Learning and Data Science in Health

July 22, 2020 09:05:02

You may have heard about machine learning and data science in different aspects of life, such as in how your insurance premiums are determined. But, did you know that machine learning and data science are playing an increasing role in public health? Read on and learn about this exciting development.

What is Big Data?

It refers to the massive amount of information, such as data from administrative health claims and biobanks, which is available to researchers in a de-identified fashion. Furthermore, it is termed as significant due to the undiluted number of people represented…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Personal Preparedness Tips for People with Bleeding Disorders

July 21, 2020

July 21, 2020 14:05:45

Personal planning and health preparedness are an essential component for everyone. However, it is more critical for individuals with bleeding problems. Some bleeding disorders, such as von Willebrand disease and hemophilia, are as a result of one lacking a specific clotting protein factor in the blood.

Due to that, people with bleeding disorders are always experiencing excessive bleeding after trauma or injury. Sometimes, they may bleed for no apparent reason at all. In emergency scenarios, their health still depends on easy access…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $2.59M NIH Research Grant to Lead Researcher Behind Its Diabetes Gene Therapy

July 21, 2020

July 21, 2020 10:21:24

Genprex (NASDAQ: GNPX), today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the company’s potentially curative diabetes gene therapy, was awarded a grant of $2.59 million from the National Institutes of Health (“NIH”) National Institute of Diabetes and Digestive and Kidney Diseases. According to the update, the grant will assist Dr. Gittes’ development for his research project titled, “Alpha Cell Conversion to Beta Cells in Non-human Primates” and build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes. “We are excited to receive this funding to support our research in diabetic primates as we move toward human clinical trials,” Dr. George Gittes, Co-Scientific Director and Professor of Surgery at the University of Pittsburgh Medical Center (“UPMC”) Children’s Hospital of Pittsburgh and the lead researcher behind the diabetes gene therapy. “We saw encouraging data in our preclinical mice studies, where the gene therapy reprogrammed pancreatic cells to restore normal blood glucose levels in diabetic mice for approximately four months, which could translate to decades in humans. More recently, preliminary results in non-human primates (monkeys) has also been very promising.”

To view the full press release, visit http://ibn.fm/lIvvG

About Genprex, Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

5 Mistakes to Avoid When Budgeting for a Clinical Trial

July 21, 2020

July 21, 2020 09:05:11

Making a concrete budget for clinical trials is always challenging yet sponsors of these clinical trials always try their best to plan adequately for every dollar they will need. However, there are still some unforeseen costs that always emerge. It is therefore always better to budget for the unseen rather than being surprised later.

Most of the established clinical research organizations have carried out many clinical pieces of research hence have the expected…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

7 Signs You Need the Services of a Contract Research Organization

July 20, 2020

July 20, 2020 14:05:40

Clinical trials may sometimes be so cumbersome, especially when you are working on it alone. Successful clinical trials require the help of a good Contract Research Organization (“CRO”). The right CRO will add great value to your research, especially while dealing with critical elements.

What is a Contract Research Organization?

It is a company that supports clinical research by providing outsourced services such as auditing, training, monitoring, data and project management. A well-established CRO will offer all the services mentioned above or even more. A CRO team can provide its support throughout…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Enters Strategic Agreement to Offer World-Class RPM Solution to HCPs Across the UK and Ireland

July 20, 2020

July 20, 2020 10:19:25

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced its entry into a new strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to Healthcare Professionals (“HCPs”) across the United Kingdom and Ireland. According to the update, Dario’s turn-key RPM solution integrates the company’s existing open platform, application technology, and the DarioEngage coaching platform, to allow Healthcare Professionals to monitor their patients remotely. “We are very excited about this partnership between DarioHealth and Williams Medical, as this aligns with our international growth initiative by offering our world-class RPM platform to physicians outside of the United States,” Dror Bacher, COO of DarioHealth, stated in the news release. “Williams’ in-depth understanding of the UK and Irish healthcare markets and strong presence in the primary care arena creates an ideal opportunity for us to deliver a best-in-class RPM solution to general practices and patients, which we believe leads to reduced HCP workload while enhancing patient care and clinical outcomes.”

To view the full press release, visit http://ibn.fm/EnSTL

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, DarioHealth empowers individuals to make adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Could Daily Aspirin Intake Prevent Colorectal Cancer?

July 20, 2020

July 20, 2020 09:05:14

The most common cause of hereditary colorectal (colon) cancer is Lynch Syndrome (“LS”). People with Lynch Syndrome have a 70% higher risk of developing colorectal cancer in their lifetime than the general population, and colorectal cancer is the leading cause of death among cancer cases in the U.S. Additionally, people with LS often develop colorectal cancer at much younger ages compared to the healthy population. However, there are no specific drugs that cure cancer, but following the set guidelines by the National Institute for Health and Care (“NICE”) in the UK, there may be some significant news. The information discussed below may offer a sigh of relief to the people suffering from colorectal cancer (“CRC”).

Clinical Trials by NICE

Recent clinical trials indicated that taking Aspirin for more than two years reduces the risk of colorectal cancer among people with Lynch Syndrome. In a clinical trial, only 4% of those who were taking daily Aspirin developed CRC as compared to the 7% under placebo group in a sample of 861 people with LS. However, adverse events did not vary significantly between the two groups. Furthermore, further studies…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

How Clinical Researchers Can Stay Productive During This Crisis

July 17, 2020

July 17, 2020 14:05:25

The normal day to day operations of all sectors have been affected by the outbreak of COVID-19, and it has made most non-essential employees resort to working from home. The medical industries have not been spared, and this has stalled a lot of clinical research. Clinical visits and schedules have also been cancelled due to this pandemic. However, clinical researchers can remain productive during this crisis through the following ways:

Engage in Training and Re-training

If it has been long since you reviewed the Code of Federal Regulations, this is the best opportunity to undertake some in-depth training. Your team should be trained on the fundamentals of good Clinical Practice to ensure that they are well equipped. The training can be done virtually under the FDA rules and regulations. Once the training on the basics is over, keep brushing on current protocols to improve your skills in handling your ongoing projects. Furthermore, start documenting what protocol…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Using Protein Biomarkers Enhances Clinical Trial Outcomes

July 17, 2020

July 17, 2020 13:54:48

It is crystal clear that clinical trials are the surest way to bring new drugs into the market. While most clinical trials are costly, nine out of ten drugs in clinical development are never approved. Most of these treatments fail in clinical trials due to a lack of the desired effect, and some of these failures are attributed to poor target selection during the drug discovery process. Matching the right treatment to the right patient based on molecular biomarkers can bring more promising results in clinical trials.

Precision Medicine Requires Reliable Biomarkers

Precision medicine aims to treat patients as individuals. It also targets treating patients in stratified groups with distinct molecular profiles. Early identification and verification of biomarkers in drug development stages will ensure that the new therapies are tested on the intended…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

An Exploration of Gene and Cell Therapy

July 16, 2020 14:05:11

Cell and gene therapies are at the frontline of advancement in personalized medicine, and they are also two overlapping fields in medical research. Gene and cell therapy aim to treat the underlying causes of both acquired and genetic disease.

Cell therapy

It is a process in which intact live cells are given to a patient through injection, graft, or implantation to relieve or eradicate a disease. It is always done by using cells to carry therapy through the body. Besides, it can also be achieved by restoring a set of cells impacted by a disease. Today, most cell therapies are based on using the patient’s cells. However, cell therapy…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

DarioHealth Corp. (NASDAQ: DRIO) Named Global Player in Digital Diabetes Management Market

July 16, 2020 12:11:30

The company was named to the list of BioSpace Movers and Shakers in July 2020 after veteran health plan executive Dennis A. Matheis joined its Board of Directors
Global digital diabetes management market is projected to register CAGR of 17.8% by 2026
DarioHealth’s platform lauded for centering on continual maximization of patient engagement

DarioHealth (NASDAQ: DRIO), a global digital therapeutics company serving its users with dynamic mobile health solutions, is in the spotlight as a major global player in the digital diabetes management market.

A recent report published by Data Bridge Market Research featured DarioHealth and its advancements in digital diabetes management – a growing global market expected to become the “next best thing” in the wake of the current coronavirus pandemic that has made it more difficult for diabetes patients to receive treatment. The market is projected to register a…

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc. Arms Clinicians, Targets Global OSA Market with Alternative Solutions

July 16, 2020 11:35:53

Vivos Therapeutics, an emerging leader in the treatment of obstructive sleep apnea (“OSA”), is positioned to capitalize on the growing global OSA market, projected to reach $13.24 billion by 2027. The company’s unique approach is to arm clinicians in treating patients suffering from OSA. A recent article discussing this reads, “The company’s oral appliances have proven to be effective in more than 15,000 patients successfully treated worldwide by approximately 1,350 trained dentists. Vivos’ vision is to provide clinicians with the tools to provide the best alternative solution to treat OSA.”

To view the full article, visit http://ibn.fm/ge0Jr

About Vivos Therapeutics Inc.

Vivos Therapeutics is an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), a debilitating condition affecting nearly 1 billion people worldwide. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep. At the core of Vivos’ mission to eradicate OSA is the Vivos System(R), a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System multidisciplinary treatment protocol involves collaboration between physicians, specially trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health-care providers. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

How Research Sites Can Be Reopened Safely

July 16, 2020 09:05:35

Many clinical researchers are still doing their work behind closed doors. Despite being in the middle of the pandemic, they have tried to keep their trials or tests going remotely and they would want to open again fully. It is not the researchers alone who are eager for the research sites to open. Other stakeholders, including interns, have found themselves in that dilemma.

For instance, in the U.S., the three-phase plan for reopening the country indicates that researchers may return to work soon. As your research teams are preparing to return to their work stations, the safety of patients and staff must be a top priority. Clear policies for how your staff will be conducting…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Trends Likely to Develop Following the Coronavirus Pandemic

July 15, 2020

July 15, 2020 14:05:12

When the coronavirus pandemic reached the U.S., the FDA reacted swiftly to come up with quick solutions. In a few weeks, emergency testing was already in place, and that was an opportunity to convert some of the machines to be used as ventilators. The pandemic has paved the way for some new changes and trends, and they are going to have a significant impact on the medical industry. Here are five medical trends we could see very soon:

Approval Time is Going to be Faster

As the FDA’s emergency testing initiative is likely to expire, a backlog in approving medical devices is expected to occur due to the effects of COVID-19 as the clinical trial activities have been slowed down. Moreover, several sponsors diverted funds from clinical testing due to a significant…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Vivos Therapeutics, Inc. Looking At Significant Forecasted Growth of Sleep Apnea Devices Market

July 15, 2020

July 15, 2020 11:25:30

Sleep apnea devices market growth also driven by the current pandemic which has made it exponentially more difficult for patients to seek treatment for their condition
Registered with the FDA as a Specification Developer, Vivos develops and markets the first non-surgical, non-invasive and cost-effective solution for the estimated billion of people globally who suffer from OSA
Vivos believes its proprietary system is poised to provide the most significant breakthrough in OSA treatment since CPAP

The global sleep apnea market is expanding rapidly, being expected to reach $13.24 billion by 2027, from $7.81 billion in 2019, exhibiting a CAGR of 6.8 percent. In a report titled “Sleep Apnea Devices Market Size . . .”, Fortune Business Insights notes that the rising cases of cardiovascular disorders and diabetes among the geriatric population are some of the primary causes of the surge in sleep apnea (http://ibn.fm/wlVz2). Additionally, a reduction in polysomnography, laboratory-based CPAP (Continuous Positive Airway Pressure) and bi-level therapy can cause a decline in diagnosis of new sleep apnea cases as well as exert a negative impact on the growth of the market. Moreover, the report cites NCBI data indicating a 50 percent decline in compliance rates for CPAP devices. This has created the need for alternative oral appliances to provide comfort to sleep apnea patients.

An emerging global leader in the treatment of obstructive sleep apnea (“OSA”), Vivos Therapeutics, Inc. is uniquely positioned to capitalize on this growing market and the increased demand for sleep apnea alternative solutions. The company’s proprietary Vivos System(R) is the first treatment modality for mild to moderate OSA in adults that does away with the need for lifelong interventions. The system’s treatment time is a fraction of that of its…

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Why it is Best to Invest in Remote Clinical Research Training Now

July 15, 2020

July 15, 2020 08:39:03

A well-trained staff is key to the integrity and success of one’s clinical trial. During busy times, budgets are usually tight. As a result, training in clinical research fails to get the attention it needs. However, training in remote clinical research is affordable. It is an effective alternative to conducting research in different geographically areas during times when movements are limited. There is therefore no time which is better in investing in remote clinical research training than right now. The main reasons why people are investing in remote clinical research training include:

Cost-Effectiveness

The different forms of online clinical research training eliminates the necessity for travel. For example, there are online courses that have been recorded in advance. They are thus the best scalable alternative to the process of hiring an instructor. Virtual trainers also have the capacity…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Why Corona Virus Scientists Are Paying Attention to Wastewater

July 14, 2020 14:20:14

COVID-19 experts have a lot of interest in what we are flushing away. Is it that wastewater could predict the second wave of SARS-COV-2 infections? Some countries, such as Germany and China, have had a second-wave of infections after strict lockdown measures were lifted. Can there be a way to predict new hotspots and curb them before spreading further? That’s what some scientists are thinking. The answer therefore, could lie beneath our feet-wastewater.

What is the relationship between wastewater and SARS-CoV-2 infections?

Wastewater-based epidemiology (WBE), also known as water monitoring, has previously been used to detect outbreaks of antibiotic-resistant bacteria, poliovirus, and measles. When one is infected with SARS-CoV-2, the virus multiplies within their body. Some viral RNA…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Why DarioHealth Corp. (NASDAQ: DRIO) Is ‘One to Watch’

July 14, 2020 10:47:17

DarioHealth (NASDAQ: DRIO) is a pioneer in the global digital therapeutics market focused on delivering evidence-based interventions to people with chronic conditions. A recent article discussing DarioHealth reads, “Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.”

To view the full article, visit http://ibn.fm/QtIUL

About DarioHealth Corp.

DarioHealth is a leading, global, digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces New Board Appointments

July 14, 2020 10:09:35

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of three new members to the company’s board of directors, effective immediately. According to the update, joining the board as independent directors are: Dr. Nancy Chung-Welch, Ph.D., Charles L. Nuzum, CPA and Greg St. Clair. “These appointments signify our absolute commitment to aligning our Board’s expertise with the company’s strategic vision of developing and commercializing an offering that will enable us to support the improvement in healthcare outcomes for oncology patients and increase value to our shareholders,” Dr. Carl Schwartz, Predictive Oncology CEO, said in the news release. “Each of these members brings a wealth of knowledge, experience and thought leadership that will be highly valuable as we execute our plans to develop and market AI-based predictive models that leverage our unique tumor bank.”

To view the full press release, visit http://ibn.fm/FHVLG

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

3 Obstacles Preventing Wider Adoption of Telemedicine

July 14, 2020 09:05:51

The ongoing COVID-19 pandemic, which has compelled lockdown orders to be issued in nearly every jurisdiction, has brought to light how certain approaches, such as telemedicine, need to play a bigger role in the way preventive medicine is provided to populations. However, the widespread adoption of telemedicine is still far from becoming a reality due to the numerous hurdles which need to be addressed. We highlight some of those obstacles.

Lack of Reimbursements

Health insurance makes the cost of getting needed care affordable, and therein lies one of the problems preventing telemedicine from taking root on a bigger scale. Most health insurance companies will only reimburse the costs…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Managing Clinical Trials Digitally

July 13, 2020

July 13, 2020 14:05:59

Digital data collection has played major roles in several aspects of our lives, reduced waste and removed room for human error. For example, airlines today transfer most of the data collection function to their customers, and we are willing (and even happy) to use our mobile devices to provide all the needed data, such as our seat preferences and other personal details. Banks have done the same, and so have other service providers. However, the field of clinical research has been slow in waking up to the immense benefits of digital data collection, and we cover some of the major considerations why this should no longer be the case.

How Mobile Devices Can Be Mobilized for Clinical Research

IT consumerization has made huge inroads into daily life, and it is now common for employees to use their own laptops and other mobile devices while doing company work. This trend can be tapped in the clinical trial space by allowing study participants…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

What is the Difference Between SaaS and Hosted EHR Solutions?

July 13, 2020

July 13, 2020 09:05:31

Are you a facility owner considering the different options available in the Electronic Health Record System space? If that’s the case, you have probably heard or seen the term “SaaS” and “Hosted” to refer to different ways of licensing EHR products. These terms are always used interchangeably, and that should not be the case. If you have heard these terms from your vendors, then you need to understand the difference.

What is SaaS?

SaaS is defined as software as a service. It is a way to deliver software to end-users who do not want the task of maintaining and running the software by themselves. SaaS systems are found on servers maintained and operated by a vendor in a data…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology Inc. (NASDAQ: POAI) Releases Q1 2020 Financial, Business Report; Revenues Up, Margins Stay Strong

July 10, 2020 14:14:19

POAI improved liquidity position, streamlined capital structure with conversion of $2.1 million convertible note
Business highlights include continued initial study to sequence ovarian tumors, validate “reach-back”
Company closed transaction resulting in gross cash proceeds of approximately $2.2 million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced Q1 2020 financial results and business highlights (http://ibn.fm/mFwpq) as well as receipt of cash proceeds of $2.2 million from exercise of warrants (http://ibn.fm/2n6x5).

“[POAI] improved our liquidity position and streamlined our capital structure with the conversion of a $2.1 million convertible note, previously held by me, to newly issued equity,” said POAI CEO Dr. Carl Schwartz…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Tips on Meeting FDA Device Design Requirements

July 10, 2020 14:05:39

Are you a device manufacturer in the medical industry? Then you may be thinking that the FDA design controls are confusing terms on your process. These regulatory design requirements shouldn’t be shrouded in confusion, and we share some tips below that will help you enjoy being a biomedical product designer who meets or even surpasses the FDA regulatory requirements.

It Would Be Best If You Didn’t Believe in Misconceptions

A heavy load of documentation has been the biggest misconception about meeting the FDA design controls. If you have volumes of documentation on how to meet FDA design requirements, then your design controls are obsolete, and they need…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc.’s Innovative System Leverages Multidisciplinary Protocol in OSA Treatment

July 10, 2020 12:55:41

Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience an increased and enhanced upper airway with the purpose of reducing tissue obstructions causing obstructive sleep apnea (“OSA”). A recent article discussing this reads, “Vivos Therapeutics Inc. offers a new and superior alternative for treating obstructive sleep apnea, and the company believes its technology represents the most important breakthrough in OSA treatment since Continuous Positive Airway Pressure (‘CPAP’), which involves the use of special face or nasal masks.”

To view the full article, visit http://ibn.fm/SjBIg

About Vivos Therapeutics Inc.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Microsurgery Robot Market Expected to Grow Exponentially